Literature DB >> 28476749

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.

Estefanía García-Guerrero1,2, Tea Gogishvili1, Sophia Danhof1, Martin Schreder1, Celine Pallaud3, Jose Antonio Pérez-Simón2, Hermann Einsele1, Michael Hudecek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28476749     DOI： 10.1182/blood-2017-03-770776

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  40 in total

Review 1.  Seeking Convergence and Cure with New Myeloma Therapies.

Authors:  Priya Choudhry; Derek Galligan; Arun P Wiita
Journal:  Trends Cancer       Date:  2018-06-27

2.  The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide.

Authors:  Subhashis Sarkar; Sachin K S Chauhan; John Daly; Alessandro Natoni; Heather Fairfield; Robert Henderson; Emma Nolan; Dawn Swan; Jinsong Hu; Michaela R Reagan; Michael O'Dwyer
Journal:  Cancer Immunol Immunother       Date:  2020-01-09       Impact factor: 6.968

3.  Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Authors:  Johannes M Waldschmidt; Alexander Keller; Gabriele Ihorst; Olga Grishina; Stefan Müller; Dagmar Wider; Anna V Frey; Kristina King; Roman Simon; Annette May; Pierfrancesco Tassone; Justus Duyster; Manfred Jung; Noopur Raje; Ralph Wäsch; Monika Engelhardt
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

4.  The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.

Authors:  Shyril O'Steen; Melissa L Comstock; Johnnie J Orozco; Donald K Hamlin; D Scott Wilbur; Jon C Jones; Aimee Kenoyer; Margaret E Nartea; Yukang Lin; Brian W Miller; Theodore A Gooley; Sherilyn A Tuazon; Brian G Till; Ajay K Gopal; Brenda M Sandmaier; Oliver W Press; Damian J Green
Journal:  Blood       Date:  2019-10-10       Impact factor: 22.113

5.  Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.

Authors:  Yi Hu; Huimin Liu; Chuanfeng Fang; Chen Li; Fjorela Xhyliu; Hayley Dysert; Juraj Bodo; Gabriel Habermehl; Benjamin E Russell; Wenjun Li; Marcia Chappell; Xiaofeng Jiang; Sarah L Ondrejka; Eric D Hsi; Jaroslaw P Maciejewski; Qing Yi; Kenneth C Anderson; Nikhil C Munshi; Geyou Ao; Jason N Valent; Jianhong Lin; Jianjun Zhao
Journal:  Cancer Res       Date:  2020-03-19       Impact factor: 12.701

Review 6.  B7-H3-targeted Radioimmunotherapy of Human Cancer.

Authors:  Benjamin B Kasten; Soldano Ferrone; Kurt R Zinn; Donald J Buchsbaum
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

Review 7.  Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy.

Authors:  Tianshu Yang; Yunkai Yang; Yan Wang
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

Review 8.  Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.

Authors:  Alessandra Romano; Paola Storti; Valentina Marchica; Grazia Scandura; Laura Notarfranchi; Luisa Craviotto; Francesco Di Raimondo; Nicola Giuliani
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

9.  CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.

Authors:  Arwen Stikvoort; Jort van der Schans; Subhashis Sarkar; Renée Poels; Ruud Ruiter; Jyoti Naik; Huipin Yuan; Joost D de Bruijn; Niels W C J van de Donk; Sonja Zweegman; Maria Themeli; Richard Groen; Michael O'Dwyer; Tuna Mutis
Journal:  Hemasphere       Date:  2021-06-12

10.  Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma.

Authors:  Nurulhuda Mustafa; Adina Huey Fang Nee; Jing Yuan Chooi; Sabrina Hui Min Toh; Tae-Hoon Chung; Viknesvaran Selvarajan; Shuangyi Fan; Siok Bian Ng; Michelle Poon; Esther Chan; Joanne Lee; Yen Lin Chee; Anand D Jeyasekharan; Longen Zhou; Jennifer Yang; Wee Joo Chng
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.